Two Tracers, Two Purposes
FDG PET CT and PSMA PET CT are both PET CT scans, but they use different radioactive tracers that target different things. The choice between them depends on the type of cancer, the clinical question, and what information the doctor needs.
Understanding the basic differences helps explain why your doctor may recommend one over the other, or in some cases, both.
FDG: Targeting Glucose Metabolism
FDG (fluorodeoxyglucose) is a modified sugar molecule. When injected, it is taken up by cells that are actively consuming glucose. Since most cancers have increased glucose metabolism compared to normal tissue, FDG highlights these metabolically active areas.
FDG PET CT is the workhorse of oncological imaging. It is used for a wide range of cancers including lung cancer, lymphoma, head and neck cancers, colorectal cancer, melanoma, and many others. It is well-established, widely available, and effective for staging, treatment monitoring, and recurrence detection across these cancer types.
PSMA: Targeting Prostate Cancer Cells
PSMA (prostate-specific membrane antigen) is a protein found in high concentrations on the surface of most prostate cancer cells. A PSMA PET CT uses a tracer that binds specifically to this protein, making it highly sensitive and specific for prostate cancer.
PSMA PET CT is primarily used for prostate cancer. It is particularly valuable for initial staging after diagnosis, detecting biochemical recurrence (when PSA rises after treatment), and determining eligibility for PSMA-targeted therapies like Lu-177 PSMA.
When FDG Is the Right Choice
For most cancers other than prostate cancer, FDG PET CT is the standard first-line scan. If you have lung cancer, lymphoma, melanoma, or other common solid tumours, your doctor will likely recommend FDG PET CT for staging and monitoring.
FDG is also useful when the specific cancer type is unknown. Because it detects metabolic activity broadly, it can help characterise lesions and identify the primary site of cancer when it has not yet been determined.
When PSMA Is the Right Choice
For prostate cancer, PSMA PET CT is generally more informative than FDG PET CT. Many prostate cancers have relatively low glucose metabolism and do not show up well on FDG scans, especially at early stages or with low-volume disease. PSMA PET CT detects prostate cancer with higher sensitivity because it targets the cancer cells directly through the PSMA protein.
PSMA PET CT is the preferred scan for prostate cancer staging, recurrence detection, and treatment planning for radioligand therapy.
Can You Need Both?
In some situations, your doctor may recommend both scans. For prostate cancer, if PSMA PET CT shows certain lesions that are PSMA-negative (which can happen with some aggressive prostate cancer variants), an FDG PET CT may provide additional information about those specific lesions. A mismatch between PSMA and FDG findings can also inform treatment decisions.
In rare cases, patients with prostate cancer and a second unrelated cancer may need both tracers for different purposes.
The Decision Is Clinical
The choice of tracer is a medical decision made by your oncologist and nuclear medicine physician based on your cancer type, stage, treatment history, and the specific clinical question they need answered. It is not a choice the patient needs to make independently.
If you are unsure why a particular scan has been recommended, ask your doctor to explain which tracer is being used and why it is the most appropriate one for your situation.